State Board of Administration of Florida Retirement System increased its position in shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 18.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,093 shares of the company’s stock after buying an additional 3,270 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Karyopharm Therapeutics were worth $405,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in KPTI. State Street Corp increased its stake in shares of Karyopharm Therapeutics by 181.2% during the third quarter. State Street Corp now owns 3,148,516 shares of the company’s stock worth $30,289,000 after buying an additional 2,028,790 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $680,000. California Public Employees Retirement System increased its stake in shares of Karyopharm Therapeutics by 68.0% during the fourth quarter. California Public Employees Retirement System now owns 304,940 shares of the company’s stock worth $5,846,000 after buying an additional 123,440 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $167,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $318,000. Hedge funds and other institutional investors own 83.55% of the company’s stock.

In related news, EVP Christopher Brett Primiano sold 26,500 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $25.37, for a total transaction of $672,305.00. Following the completion of the sale, the executive vice president now directly owns 36,867 shares of the company’s stock, valued at $935,315.79. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $18.61, for a total value of $186,100.00. Following the sale, the chief executive officer now directly owns 565,122 shares of the company’s stock, valued at $10,516,920.42. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,500 shares of company stock valued at $1,083,605. Corporate insiders own 13.26% of the company’s stock.

KPTI stock opened at $20.65 on Friday. The company has a market capitalization of $1.40 billion, a P/E ratio of -7.07 and a beta of 1.60. Karyopharm Therapeutics Inc has a twelve month low of $5.14 and a twelve month high of $29.61. The business has a 50 day simple moving average of $20.67 and a 200-day simple moving average of $18.34. The company has a current ratio of 7.46, a quick ratio of 7.44 and a debt-to-equity ratio of 0.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.09). The firm had revenue of $18.14 million during the quarter, compared to analyst estimates of $21.59 million. Karyopharm Therapeutics had a negative net margin of 316.53% and a negative return on equity of 208.07%. Research analysts predict that Karyopharm Therapeutics Inc will post -2.39 EPS for the current fiscal year.

Several equities analysts have commented on KPTI shares. SVB Leerink dropped their price target on shares of Karyopharm Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Barclays started coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, March 4th. They issued an “overweight” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Thursday, May 14th. Royal Bank of Canada reiterated a “buy” rating and issued a $34.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, April 13th. Finally, ValuEngine upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $29.44.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

See Also: What are economic reports?

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.